Abstract
Abstract
This study provides econometric evidence about the impact that new chemical entity (NCE) launches had on premature mortality from 17 diseases in 9 Middle Eastern and African countries during the period 2007–2015.
The greater the relative number of NCEs for a disease launched in a country, the greater the subsequent relative decline in premature mortality from that disease, controlling for the average rate of mortality decline in each country and from each disease.
An 8-year increase in the number of post-1992 NCEs ever launched is estimated to have reduced the number of years of potential life lost before age 75 (YPLL75) in 2015 by 9.5 %. This is approximately half of the 18.9 % reduction in YPLL75, and about one-third of the 29.7 % reduction in the premature mortality rate. In the absence of 8 previous years of NCE launches, 2.80 million additional YPLL before age 75 would have been lost in 2015.
Expenditure on new drugs per life-year below age 75 gained in 2015 from the drugs was $US 834. According to the standards of the WHO’s Choosing Interventions that are cost–effective project, new drugs launched in the nine ME&A countries were very cost–effective overall.
Reference58 articles.
1. The ‘Embodiment’ Controversy: A Review Essay;Journal of Monetary Economics,1998
2. The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Switzerland, 1995–2012;European Journal of Health Economics,2016
3. Irving Fisher and the Contribution of Improved Longevity to Living Standards;American Journal of Economics and Sociology,2005
4. The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia;Economic Record,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献